CRISPNA PNA Guide Molecule Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
CRISPR systems face challenges with off-target mutations due to the instability and non-specific binding of RNA molecules, leading to unwanted DNA modifications and reduced reproducibility in genome editing applications.
Innovation Solution
The use of Peptide Nucleic Acids (PNAs) to direct Cas proteins to their DNA or RNA targets instead of RNA molecules, forming CRISPNA technology, which offers enhanced stability and specificity by replacing crRNAs or sgRNAs with PNAs, thereby improving the efficacy and specificity of genome editing and diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNA molecules (crRNA/sgRNA) are used to direct Cas proteins to target DNA, then the system can achieve genome editing functionality, but off-target mutations occur due to RNA instability and non-specific binding
Solution Approach 1:
The patent changes the chemical parameters of the guide molecule from RNA to PNA (peptide nucleic acid). PNA has a peptide-based backbone instead of sugar-phosphate, which fundamentally alters its binding properties: it forms more stable hybridization with complementary DNA/RNA sequences and exhibits higher specificity, thereby reducing off-target effects while maintaining on-target editing efficiency
Solution Approach 2:
The invention creates a composite guide molecule structure by combining PNA (peptide nucleic acid) with the CRISPR-Cas system. This composite approach integrates the high stability and specificity of PNA with the genome editing capability of Cas proteins, resulting in a CRISPNA system that overcomes the limitations of pure RNA-based guides
2Reliability
If RNA molecules are used as guides, then the CRISPR system can be implemented, but the RNA instability reduces reproducibility of genome editing
Solution Approach 1:
The patent changes the chemical composition and stability parameters of the guide molecule from labile RNA to chemically stable PNA. The peptide backbone of PNA confers resistance to nucleases and chemical degradation, dramatically improving molecular stability and ensuring consistent, reproducible genome editing results across different experimental conditions and time points
3Manufacturing precision
If RNA molecules direct Cas proteins to targets, then genome editing can be achieved, but non-specific binding reduces editing precision
Solution Approach 1:
The patent modifies the binding parameters by replacing RNA with PNA, which exhibits enhanced specificity due to its peptide backbone structure. This structural change results in stronger, more specific hybridization with complementary sequences and reduced non-specific binding, thereby improving the precision of genome editing at the intended target sites
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CRISPNA technology provides more stable and specific binding to target sequences, reducing off-target effects and enhancing the precision of genome editing and diagnostic applications, including gene therapy and disease treatment.
Implementation Method 1
Peptide Nucleic Acids (PNAs) to direct the Cas proteins to their DNA or RNA targets
Implementation Method 2
Cas9 functions as an RNA-guided endonuclease that uses a dual-guide RNA consisting of crRNA and trans-activating crRNA (tracrRNA) for target recognition and cleavage
Data Source
AI summary
CRISPNA, a new tool for genome editing and diagnosis. The present invention relates to methods and systems for genome editing and diagnosis, and specifically relates to use of Peptide Nucleic Acids (PNAs) to direct the Cas proteins to their DNA or RNA targets.